MENLO PARK, Calif.--(BUSINESS WIRE)--CohBar, Inc. (OTCQX: CWBR and TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today reported financial results for the three months ended June 30, 2015.
“We took significant steps this quarter that enhance our ability to create potential breakthrough therapeutics including expanding our team of highly experienced scientists and completing the transition to our new lab facility,” said Jon Stern, CohBar CEO.
Help employers find you! Check out all the jobs and post your resume.
